AB Science S.A.
Other OTCCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Alain Moussy
- Full Time Employees
- 36
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Address
- 3, Avenue George V Paris IF France 75008
- IPO Date
- Sep 9, 2011
- CIK
- 0001703850
- Website
- ab-science.com
- Similar Companies
- Business
- AB Science S.A. (Euronext: AB) is a clinical-stage French pharmaceutical company that researches, develops and commercializes protein kinase inhibitors and related targeted therapies for cancers, inflammatory diseases, neurodegenerative disorders and other conditions with high unmet medical needs in humans and veterinary medicine; its lead product masitinib, a highly selective tyrosine kinase inhibitor already approved for veterinary use, advances in late-stage human trials for amyotrophic lateral sclerosis (ALS), multiple sclerosis, oncology and other indications including a new confirmatory Phase 3 study (AB23005) authorized by the FDA and select European countries in 2025, while its second key compound AB8939, a next-generation microtubule destabilizer, progresses through Phase 1/2 in acute myeloid leukemia (AML) with promising early efficacy data and plans for an expansion cohort. Founded in 2001 and headquartered at 3 Avenue George V in Paris, France, the company employs around 40 staff primarily focused on R&D, operates globally through clinical programs in Europe, North America and beyond including a U.S. subsidiary in New Jersey, and markets masitinib for veterinary applications while pursuing human approvals. Recent developments include multiple 2025 capital raises totaling over EUR 9 million through private placements and its PACT program with Alpha Blue Ocean to fund AB8939 advancement and masitinib studies, ongoing re-examination of masitinib marketing authorizations for ALS with the EMA and Health Canada, and operational restructuring to prioritize its dual-platform pipeline amid reduced bank debt.
AB Science is invited to present at the 2026 ENCALS annual meeting the survival data from masitinib clinical program in ALS
AB Science : Stonegate Capital Partners updates its coverage of AB Science's stock with a target price of EUR 4.25 per share
AB Science announces that its stock continues to be covered by Maxim Group, with a target price of €4.00 per share
AB Science reports its revenues for the year 2025 and provides an update on its activities
AB Science announces the successful completion of a EUR 3.2 million private placement
AB Science announces a final agreement on the renegotiation of the repayment terms of its loans with all of its financial creditors
AB Science: New publication on medrxiv demonstrating substantial survival benefits and preserved quality of life with masitinib in ALS patients
AB Science provides an update on its clinical development program.
AB Science announces the identification of a plasma biomarker that indicates the activity of masitinib in treating ALS
Stonegate Capital Partners Initiates Coverage on AB Science S.A. (AB)
AB Science announced that the Food and Drug Administration (FDA) granted the status of Minor Use in Major Species (MUMS) for Masivet® in the treatment of canine mast cell tumors
AB Science receives Japanese patent protection for the use of masitinib in progressive forms of multiple sclerosis (MS) until 2041
AB Science reports fourth consecutive case of response from Phase 1 data for the combination of AB8939 with venetoclax for the treatment of refractory or relapsed acute myeloid leukemia
AB Science patent for masitinib in the treatment of sickle cell disease formally granted in the US with a protection until 2040
AB Science announces the initiation of coverage of its stock by Maxim Group with a target price of EUR 4.0 per share
AB Science announces a new publication on biorxiv that identifies AB8939 as a promising drug candidate for treating refractory acute myeloid leukemia and potentially other cancers
AB Science announces new publication on Medrxiv highlighting clinical benefit with masitinib in Amyotrophic Lateral Sclerosis patients prior any complete loss of function
AB Science announces the successful completion of a EUR 2.8 million private placement